NeoGenomics (NASDAQ:NEO) was upgraded by BTIG Research from a “neutral” rating to an “outperform” rating in a research note issued on Monday, April 16th, MarketBeat reports.
Other equities research analysts have also issued research reports about the company. Canaccord Genuity lifted their price objective on NeoGenomics from $23.00 to $24.00 in a research note on Tuesday, March 13th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. CIBC set a $19.00 price objective on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada set a $23.00 price objective on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. NeoGenomics currently has an average rating of “Buy” and an average price target of $17.29.
NEO stock opened at $9.39 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.21 and a current ratio of 2.42. The company has a market capitalization of $752.51, a PE ratio of 155.67, a P/E/G ratio of 4.83 and a beta of 0.42. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $11.63.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.02. The business had revenue of $67.79 million during the quarter, compared to the consensus estimate of $66.32 million. NeoGenomics had a positive return on equity of 4.34% and a negative net margin of 1.37%. The business’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period last year, the business posted $0.05 earnings per share. equities research analysts anticipate that NeoGenomics will post 0.1 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas bought a new stake in shares of NeoGenomics in the 4th quarter worth approximately $182,000. Howland Capital Management LLC lifted its position in NeoGenomics by 67.6% in the 4th quarter. Howland Capital Management LLC now owns 21,782 shares of the medical research company’s stock valued at $193,000 after acquiring an additional 8,782 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in NeoGenomics in the 4th quarter valued at approximately $235,000. Aperio Group LLC bought a new position in shares of NeoGenomics during the 4th quarter valued at $243,000. Finally, Stone Ridge Asset Management LLC bought a new position in shares of NeoGenomics during the 4th quarter valued at $281,000. 84.24% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/25/neogenomics-neo-stock-rating-upgraded-by-btig-research.html.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.